ALR TECHNOLOGIES, INFINOVO SIGN MOU, MAKING MAIDEN CGM FOR DIABETIC PETS

KUALA LUMPUR, Dec 8 (Bernama) -- ALR Technologies (ALRT or the Company), the diabetes management company has announced the signing of a Memorandum of Understanding (MOU) with Infinovo Medical Co Ltd for a global supply agreement of their P3 Continuous Glucose Monitor (CGM) for use by ALRT in the animal health sector.

Under the terms of the MOU, ALR Technologies and Infinovo will collaborate to integrate Infinovo’s P3 CGM with ALRT’s proprietary GluCurve platform. The Company expects to begin testing the GluCurve Pet CGM in veterinary clinics in late December or early January. The testing is scheduled to complete by February-end.

“We are excited to take this significant step forward with Infinovo,” said Sidney Chan, Chairman and CEO of ALRT in a statement.

“By combining the talents, strengths, and resources of both companies, we anticipate bringing the GluCurve Pet CGM to market much faster than previously expected. We are planning to commence commercial delivery as early as June, 2022.

“Working with Infinovo will provide ALRT the cutting edge hardware needed for our GluCurve Pet CGM in order to provide veterinarians the solution to diabetes management they are desperately seeking.”

Joe Stern, Head of Animal Health at ALR Technologies continued, “My team is thrilled to work with Infinovo and to begin commercial testing of the GluCurve Pet CGM in the coming weeks. “

More information about ALR Technologies Inc can be found at www.alrt.com.

-- BERNAMA